InSphero’s 3D InSight human liver model described in Archives of Toxicology InSphero’s novel multi-cell type human liver microtissue model was described recently in Archives of Toxicology. The model makes long term repeated-dose and inflammation-mediated toxicity testing possible. View open access publication.
InSphero ranked #2 'Startup of the Year' in Switzerland Around 100 experts from the Swiss business startup scene have ranked InSphero as number 2 startup in Switzerland and, for the second year running, number 1 startup in the biotech space. Read more here.
InSphero is moving to new headquarters and expanding production Great news! At the end of the year InSphero is going to move to a new, bigger facility in the Zurich area with lots of room for more staff, offices and equipment! Find new address here.
InSphero invited by SLAS to give Short Course on 3D cell-based Assays InSphero is delighted to have been invited to give a short course on 3D cell-based models for drug de-risking during the SLAS Annual Meeting 2013. Click for course details.
3D cell culture literature picks – Nov 2012 Our applications team has reviewed a small selection of current 3D-cell-culture journal papers to keep you updated about recent developments in 3D.
Job openings: fascinated by 3D cell culture?
Why not join us? InSphero is keen to hear from motivated people who'd like to join the company. If you're interested please send a CV and cover letter to us. Find current opportunities and contact details.
InSpherois a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 7 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy (e.g. in oncology) and toxicology, including long-term and inflammation-mediated toxicity. A broad portfolio of tumor and liver microtissues is available from a number of cell sources, with additional toxicology models in the pipeline. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognised for its scientific and commercial achievements with a number of national and international awards and is also certified to the ISO 9001:2008 standard for its Quality Management System.
Our mailing address is:
74 Orion St
Copyright (C) 2012 InSphero Inc. All rights reserved.